These experimental results confirm that PRMT6 and YTHDF2 promote the EMT and invasive phenotype of glioblastoma in vivo, and PRMT6 promotes tumor malignancy in vivo by regulating the expression of YTHDF2. Here, YTHDF2 is linked to neoplasm.